Quantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis
Authors' conclusion
GLP-1RAs demonstrated effective weight management in both nondiabetic and T2D populations. Retatrutide achieved the most pronounced weight reduction, followed by tirzepatide. GLP-1RAs also significantly improved glycemic control for patients with T2D, with tirzepatide performing the best for glycemic control.
Study context
- Population
- Adults with no diabetes or T2D in trials of GLP-1 RAs; PubMed, CENTRAL and Embase from inception to January 6, 2024
- Participants
- 56,683 adults137 trials
- Comparison
- GLP-1 RAs compared on weight loss and glycaemic control
- Outcome
- Δ body weight
Methodological detailslongitudinal analysis, five mathematical models, 310 treatment arms, 17 GLP-1 RAs
- Longitudinal analysis
- Five mathematical models
- 310 treatment arms, 17 GLP-1 RAs
Pooled result
As reported in the abstract
Most effective treatment: retatrutide (12 mg qw), mean difference
−26.56%
95% CI −43.89% to −3.01%
Tirzepatide (15 mg qw) ΔBW-NDOOG
−22.76%
−26.45% to −18.50%
Tirzepatide (15 mg qw) ΔBW-T2DCG
−11.09%
−12.39% to −9.44%
Tirzepatide (15 mg qw) ΔBW-T2DAG
−4.97%
−5.84% to −4.12%
Further pooled results
ΔHbA1c
- Most effective drugs: tirzepatide (10 mg qw) and oral orforglipron (10 mg qd), respectively
Covariate effects
- Higher baseline body weight tended to give better weight loss; higher baseline HbA1c tended to give better glucose control
Original publication
Quantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis. Diabetes Technol Ther. Published 6 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →